1. Home
  2. CHW vs FULC Comparison

CHW vs FULC Comparison

Compare CHW & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Global Dynamic Income Fund

CHW

Calamos Global Dynamic Income Fund

HOLD

Current Price

$8.25

Market Cap

523.0M

Sector

Finance

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$7.45

Market Cap

535.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHW
FULC
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
523.0M
535.5M
IPO Year
2007
2019

Fundamental Metrics

Financial Performance
Metric
CHW
FULC
Price
$8.25
$7.45
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$16.38
AVG Volume (30 Days)
232.2K
916.8K
Earning Date
01-01-0001
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.30
$3.55
52 Week High
$8.34
$15.74

Technical Indicators

Market Signals
Indicator
CHW
FULC
Relative Strength Index (RSI) 67.10 44.20
Support Level $7.90 $7.40
Resistance Level $8.27 $8.24
Average True Range (ATR) 0.14 0.48
MACD 0.04 0.00
Stochastic Oscillator 91.80 30.51

Price Performance

Historical Comparison
CHW
FULC

About CHW Calamos Global Dynamic Income Fund

Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities, and alternative investments.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: